Production of interleukin-6, tumor necrosis factor α and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients
- 1 February 1995
- journal article
- Published by Elsevier BV in Kidney International
- Vol. 47 (2), 559-565
- https://doi.org/10.1038/ki.1995.70
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- T cell activation defect in hemodialysis patients: Evidence for a role of the B7/CD28 pathwayKidney International, 1993
- Gene expression of interleukin-1β during hemodialysisKidney International, 1993
- Cytokines: Agents provocateurs in hemodialysis?Kidney International, 1992
- Serum Interleukin-6 in Long-Term Hemodialyzed PatientsNephron, 1992
- Induction of tumour necrosis factor-alpha during haemodialysis. Influence of the membrane typeClinical and Experimental Immunology, 1991
- Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRFIScience, 1990
- Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor αKidney International, 1990
- The Effect of Membrane Characteristics on Tumour Necrosis Factor Kinetics During HaemodialysisNephrology Dialysis Transplantation, 1990
- Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired primary immune responses.JCI Insight, 1987
- Active hepatitis B vaccination of dialysis patients and medical staffKidney International, 1984